# Predictive Role of Circulating Angiogenic Factors for Second-line Paclitaxel and Ramucirumab.

> **NCT05301465** · — · UNKNOWN · sponsor: **University of Pisa** · enrollment: 50 (estimated)

## Conditions studied

- Gastric Cancer Stage IV

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05301465
- **Lead sponsor:** University of Pisa
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-01
- **Primary completion:** 2022-11-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05301465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05301465, "Predictive Role of Circulating Angiogenic Factors for Second-line Paclitaxel and Ramucirumab.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05301465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*